STATCenter·
STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug
Shares of ProMis Neurosciences, developer of a treatment for Alzheimer’s disease, sold off sharply last week. A closer look at the reason why — and whether it holds up.
Read at STAT →
